We could also demonstrate a shift from CD3−CD56+dim NK cells (Fig. 4D) to less cytotoxic CD56bright NK-cell phenotypes in CASPR2-/LGI1-AIE CSF compared with IIH but not MS control patients (Fig. 4E). This evidence concerns the gene CNTNAP2 and myeloid sarcoma.